

Pegloxenatide

Cat. No.:	HY-P3491
CAS No.:	2420483-82-3
Molecular Formula:	$(C_2H_4O)_n(C_2H_4O)_nC_{206}H_{317}N_{55}O_{67}S$
Sequence:	PEGn-His-{d-Ala}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-{Nle}-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Gln-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Cy <small>PEGn-H-(D-Ala)-EGTFTSDLSKQ-(Nle)-EEEAVRLFIEWLKQGGPSSGAPPPC-NH₂</small>
Sequence Shortening:	PEGn-H-{d-Ala}-EGTFTSDLSKQ-{Nle}-EEEAVRLFIEWLKQGGPSSGAPPPC-NH ₂
Target:	GLP Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Pegloxenatide is a glucagon-like peptide-1 receptor (GLP-1 RA) agonist. Pegloxenatide can be used for type 2 diabetes research ^[1] .
--------------------	---

REFERENCES

[1]. X-Y Li, et al. Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity. *Eur Rev Med Pharmacol Sci.* 2022, 26, 21.

[2]. Lei Liu, et al. Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China. *Diabetes Ther.* 2023, 14, 1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA